ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.The Lancet. Neurology · 2026Article
- Optimizing cutoffs for clinical interpretation of brain amyloid status using PET/MRI: a multisite study.Alzheimer's research & therapy · 2026Article
- Predicting Preclinical Cognitive Decline Using Plasma P-tau217 andmedRxiv : the preprint server for health sciences · 2026Article
- Plasma proteomics ofmedRxiv : the preprint server for health sciences · 2026Article
- APOE4 Accelerates Menopause-Associated Brain Metabolic Shift and Disrupts Bioenergetic Adaptation.bioRxiv : the preprint server for biology · 2026Article
- ApoE4 Drives Microglial Lipid Dysregulation in Alzheimer's Disease via Epigenetic Reprogramming of the Asxl1/LXRα-H3K4me3 Axis.Journal of neuroinflammation · 2026Article
- Identification of Shared Gene Signatures Associated with Alzheimer's Disease and COVID-19 through Bioinformatics Analysis.Combinatorial chemistry & high throughput screening · 2026Article
- APOE4 accelerates menopause-associated brain metabolic shift and disrupts bioenergetic adaptation.Frontiers in aging neuroscience · 2026Article
- Clinical and neuropsychological profile of Alzheimer's disease in Tunisia and the impact ofFrontiers in genetics · 2026Article
- Article
- Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.Neurology · 2025Article
- Age-dependent interactions of APOE isoform 4 and Alzheimer's disease neuropathology: findings from the NACC.Acta neuropathologica communications · 2025Article
- Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Altered Heme and Redox Homeostasis Underpin Late-onset Alzheimer's Disease.International journal of biological sciences · 2025Article
- Article
- Previous parity differentially influences cognition in later life depending on dementia status.NPJ dementia · 2025Article
- Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway.Nature neuroscience · 2024Review
- Is Alzheimer disease a disease?Nature reviews. Neurology · 2024Review
- Olfactory and cognitive decrements in 1991 Gulf War veterans with gulf war illness/chronic multisymptom illness.Environmental health : a global access science source · 2024Article
- Alzheimer's genes in microglia: a risk worth investigating.Molecular neurodegeneration · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe studied the effect of apolipoprotein E (APOE) ε4 status and sex on age of symptom onset (AO) in early- (EO) and late- (LO) onset Alzheimer's disease (AD).
methodA total of 998 EOAD and 2562 LOAD participants from the National Alzheimer's Coordinating Center (NACC) were included. We used analysis of variance to examine AO differences between sexes and APOE genotypes and the effect of APOE ε4, sex, and their interaction on AO in EOAD and LOAD, separately.
resultsAPOE ε4 carriers in LOAD had younger AO and in EOAD had older AO. Female EOAD APOE ε4 carriers had older AO compared to non-carriers (P < 0.0001). There was no difference for males. Both male and female LOAD APOE ε4 carriers had younger AO relative to non-carriers (P < 0.0001).
conclusionThe observed earlier AO in EOAD APOE ε4 non-carriers relative to carriers, particularly in females, suggests the presence of additional AD risk variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.